瘦腰大肌面积与胸腹主动脉瘤开放手术患者并发症和死亡率的相关性
该回顾性研究纳入2018至2022年连续179例择期胸腹主动脉瘤开放手术患者,利用术前CTA测量瘦腰大肌面积(LPMA),分析其与30天、90天死亡及主要不良事件(MAE)和随访死亡率的相关性。结果未观察到LPMA与死亡或MAE有统计学显著相关,仅肌少症组30天死亡率有升高趋势(10% vs 2.2%,p=0.059)。作者认为LPMA不能作为独立的预后预测指标,需进一步研究。
要点
- 179例开放胸腹主动脉瘤修复患者中,30天和90天死亡率分别为6.1%和8.9%。
- LPMA中位数为330 cm2/HU,男性显著高于女性(p=0.001)。
- LPMA与30天、90天及随访死亡或MAE均无统计学显著相关。
核心结论
- 在该组开放胸腹主动脉瘤修复患者中,LPMA被认定为不能作为并发症和死亡率的独立预测指标。
- 作者指出需要进一步研究以明确该参数作为不良结局预测指标的作用。
研究设计与样本
- 回顾性分析2018年至2022年所有连续择期接受开放胸腹主动脉瘤修复且术前有可用CTA的患者。
- 利用CTA数据测量瘦腰大肌面积(LPMA),收集术前和术后变量。
- 主要终点为30天和90天的死亡及主要不良事件(MAE),次要终点为随访死亡率。
- 共纳入179例患者,其中61.5%(110/179)为II型和III型胸腹主动脉瘤。
主要发现
- 30天和90天死亡率分别为6.1%和8.9%。
- 中位随访38个月(范围12-60个月)时死亡率为17.2%。
- 30天和90天MAE发生率分别为29.1%和37.4%。
- LPMA中位数为330 cm2/HU(四分位距264,442),男性显著高于女性(p=0.001)。
- 按LPMA分为肌少症组(<350 cm2/HU)和非肌少症组(>350 cm2/HU)并分四分组,30天、90天及随访时LPMA与死亡或MAE均无统计学显著相关;肌少症组30天死亡率有升高趋势(10%,9/90) vs 无肌少症组(2.2%,2/89)(p=0.059)。
关键数值与推荐
- 肌少症定义为LPMA <350 cm2/HU,非肌少症为>350 cm2/HU。
- 30天死亡率:肌少症组10%(9/90) vs 非肌少症组2.2%(2/89),p=0.059。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sarcopenia is gaining interest in the pre-operative evaluation of patients with thoraco-abdominal aortic aneurysm (TAAA). Lean psoas muscle area (LPMA) has emerged as a way to measure sarcopenia and is a possible predictor of outcomes in endovascular TAAA repair. The aim of this study was to analyse the correlation between LPMA and outcomes of open TAAA repair. METHODS: Between 2018 and 2022, all consecutive elective patients who underwent open TAAA repair with an available adequate pre-operative computed tomography angiogram (CTA) were analysed retrospectively. The CTA data were used to measure LPMA. Pre- and post-operative variables were collected from all patients. Primary endpoints were death and major adverse events (MAEs) at 30 days and 90 days. The secondary endpoint was follow up mortality rate. Primary and secondary endpoints were correlated with LPMA. RESULTS: A total of 179 patients were included, and 61.5% (110/179) were treated for extent II and III TAAA. Death at 30 days and 90 days was 6.1% and 8.9%, respectively. At a median follow up of 38 months (range: 12 - 60), the mortality rate was 17.2%. The proportion of patients with MAE occurrence at 30 days and 90 days was 29.1% and 37.4%, respectively. The median LPMA was 330 cm2/Hounsfield unit (HU) (interquartile range 264, 442) and was significantly higher in men than in women (p = .001). Patients were divided according to the LPMA value into sarcopenic (< 350 cm2/HU) and non-sarcopenic (> 350 cm2/HU) groups, and in four quartiles. No statistically significant correlation between LPMA and death or MAEs was observed at 30 days and 90 days, and at follow up, but a trend towards an increased mortality rate was observed in patients with sarcopenia at 30 days (10%; 9/90) compared with patients without sarcopenia (2.2%, 2/89) (p = .059). CONCLUSION: In this series of patients who underwent open TAAA repair, LPMA was found to be ineffective as an independent predictor of morbidity and mortality. Further studies are needed to clarify the role of this parameter as a predictor of adverse outcomes.
引用
- Valente FBA, Rinaldi E, Santoro A, et al. Correlation Between Lean Psoas Muscle Area and Incidence of Morbidity and Mortality in Patients Undergoing Thoraco-Abdominal Aortic Aneurysm Open Surgery. Eur J Vasc Endovasc Surg. 2025. PMID: 39892851. doi:10.1016/j.ejvs.2025.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。